Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M 

TLDR

• Telix H1 revenue rises 22% to $477M as adjusted EBITDA jumps 146% year over year.
• Precision Medicine revenue climbs 27% as Illuccix and Gozellix drive higher sales.
• Telix invests $124M in R&D while advancing prostate, kidney and brain programs.
• Manufacturing revenue reaches $146M as Telix expands its global production footprint.
• Telix ends June with $252M in cash after generating $23M in operating cash flow.

Telix Pharmaceuticals posted stronger first-half results as revenue and adjusted EBITDA rose sharply from the previous year. TLX stock climbed 2.48% to $12.42, recovering from a mid-morning low near $12.10. The company also advanced several cancer programs while expanding its manufacturing network and strengthening its balance sheet.

Telix Pharmaceuticals Limited, TLX

Telix Revenue Rises 22% as Margins Improve

Telix reported first-half group revenue of $477 million, representing a 22% increase from the previous year. The result tracked near the upper end of the company’s full-year revenue guidance. Telix currently expects annual revenue between $950 million and $970 million.

Group gross margin increased two percentage points to 55% during the reporting period. Precision Medicine gross margin reached 65%, gaining one percentage point from a year earlier. Higher product volumes, product mix changes, and operating efficiencies supported the margin improvement.

Adjusted EBITDA jumped 146% year over year to $52 million during the first half. The figure included a $40 million non-refundable payment linked to Telix’s Regeneron collaboration. Telix continued investing heavily, directing $124 million toward research and development programs.

Precision Medicine Drives Commercial Growth

Telix’s Precision Medicine business increased revenue by 27% from the same period last year. Illuccix and Gozellix generated higher sales volumes while expanding their positions within prostate cancer imaging. As a result, segment adjusted EBITDA increased 26% to $132 million.

At the same time, Telix advanced several regulatory programs across major international markets. The company completed enrollment for an Illuccix Phase 3 study in Japan. Chinese regulators also accepted the company’s Illuccix application and started their formal review process.

Telix also moved its brain and kidney cancer imaging products through additional regulatory milestones. The FDA assigned Pixclara a September 11, 2026, decision target date. Separately, Telix continues preparing its Zircaix application for resubmission after addressing outstanding FDA requirements.

Therapeutics Pipeline and Manufacturing Expand

Telix invested $68 million of total research spending into its therapeutics pipeline during the first half. Its ProstACT Global program met initial safety and dosimetry goals for its lead prostate cancer therapy. The FDA also cleared the program to advance into the next trial stage.

Elsewhere, the OPTIMAL-PSMA Phase 2 study completed enrollment of 120 patients with advanced prostate cancer. Telix also dosed initial patients in studies involving prostate, kidney and brain cancer therapies. These programs form part of the company’s strategy to develop revenue beyond diagnostic imaging products.

Telix Manufacturing Solutions generated $146 million in total segment revenue during the period. That figure included $89 million from external sales and services, alongside $58 million in internal revenue. However, the segment recorded a $23 million adjusted EBITDA loss following higher infrastructure and logistics investment.

The company also expanded production capacity across Australia, Belgium, Japan, and the United States. Its Seneffe facility completed its first GMP production run involving a lutetium-based therapeutic candidate. Meanwhile, Telix ended June with $252 million in cash and generated $23 million in positive operating cash flow.

The post Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M  appeared first on Blockonomi.